Notice of Closed Meeting, 2439-2440 [2022-00718]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 10 / Friday, January 14, 2022 / Notices
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
CE22–006, Research Grants to Evaluate
the Effectiveness of Physical Therapybased Exercises and Movements Used to
Reduce Older Adults Falls (U01).
Date: May 17–18, 2022.
Time: 8:30 a.m., EDT.
Place: Web Conference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Aisha L. Wilkes, M.P.H., Scientific
Review Official, National Center for
Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341,
Telephone (404)639–6473, AWilkes@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–00723 Filed 1–13–22; 8:45 am]
2439
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel;
(SEP)— CE22–003, Rigorously
Evaluating Programs and Policies to
Prevent Child Sexual Abuse (CSA).
Date: April 19–20, 2022.
Time: 8:30 a.m., EDT.
Place: Web Conference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Aisha L. Wilkes, M.P.H., Scientific
Review Official, National Center for
Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341,
Telephone: (404)639–6473, AWilkes@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–CE–22–010: Rigorous Evaluation
of Strategies to Prevent Overdose
through Linking People with Illicit
Substance Use Disorder to Recovery
Support Services.
Date: June 14–15, 2022.
Time: 8:30 a.m.–5:30 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Mikel Walters, Ph.D., Scientific Review
Official, National Center for Injury
Prevention and Control, CDC, 4770
Buford Highway NE, Mailstop F–63,
Atlanta, Georgia 30341, Telephone (404)
639–0913, MWalters@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–00716 Filed 1–13–22; 8:45 am]
[FR Doc. 2022–00724 Filed 1–13–22; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
lotter on DSK11XQN23PROD with NOTICES1
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
VerDate Sep<11>2014
18:04 Jan 13, 2022
Jkt 256001
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
E:\FR\FM\14JAN1.SGM
14JAN1
2440
Federal Register / Vol. 87, No. 10 / Friday, January 14, 2022 / Notices
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel;
(SEP)—CE22–009, Rigorous Evaluation
of Community-Level Substance Use and
Overdose Prevention Frameworks that
Incorporate ACEs-Related Prevention
Strategies.
Date: April 26–27, 2022.
Time: 8:30 a.m., EDT.
Place: Web Conference..
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Aisha L. Wilkes, M.P.H., Scientific
Review Official, National Center for
Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341,
Telephone (404)639–6473, AWilkes@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–00718 Filed 1–13–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Award of a Single-Source
Cooperative Agreement To Fund the
All-India Institute for Medical Sciences,
New Delhi (AIIMS, New Delhi)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS), announces the
award of approximately $2,000,000,
with an expected total funding of
approximately $10,000,000 over a fiveyear period, to AIIMS, New Delhi. The
award will support research to estimate
the incidence of influenza and other
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:04 Jan 13, 2022
Jkt 256001
respiratory viruses (such as SARS-CoV–
2) among working-age adults and other
priority populations in India to
strengthen the evidence base and inform
influenza vaccine policy in India.
DATES: The period for this award will be
September 30, 2022, through September
29, 2027.
FOR FURTHER INFORMATION CONTACT:
Amy Yang, Ph.D., National Center for
HIV, Viral Hepatitis, STD and TB
Prevention, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS US8–1, Atlanta, GA 30329,
Telephone: 404–718–8835, email: corp_
erpo_8835@cdc.gov.
SUPPLEMENTARY INFORMATION: This
single-source award will allow the
recipient to conduct research to estimate
the incidence of influenza and other
respiratory viruses (such as SARS-CoV–
2) among working-age adults and other
priority populations in India to
strengthen the evidence base and inform
influenza vaccine policy in India.
AIIMS, New Delhi, is in a unique
position to conduct this work, as it is
the only institution in India with the
required scientific and technical
expertise to conduct multi-site cohort
studies on influenza and other
respiratory viruses like SARS-CoV–2
which require robust epidemiological
and laboratory capacity and maintains
the high research standards required by
CDC. AIIMS, New Delhi, is
governmentally mandated by the AIIMS
Act of 1956 and operates autonomously
as an institution of national importance
under the Ministry of Health and Family
Welfare. AIIMS, New Delhi, is the
leader of basic, clinical, and
translational medical research in India.
Summary of the Award
Recipient: The All-India Institute for
Medical Sciences, New Delhi (AIIMS,
New Delhi).
Purpose of the Award: The purpose of
this award is to support research to
estimate the incidence of influenza and
other respiratory viruses, such as severe
acute respiratory syndrome coronavirus
2 (SARS-CoV–2), among working-aged
adults and other priority populations in
India to strengthen the evidence base to
help inform influenza vaccine policy in
India. The recipient will set up a multicenter hospital-based platform in India
to estimate the disease and economic
burden of influenza- and COVID–19associated hospitalization of working
age adults (18–60 years) in India. An
additional goal is to increase awareness
about influenza burden and prevention
methods among clinicians and public
health practitioners. This project aligns
with activities conducted under the
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
CDC Influenza Division’s International
Program to build the evidence base for
better understanding the disease and
economic burden of influenza and to
identify strategies for influenza
prevention, including vaccination in
low- and middle-income settings.
Amount of Award: $2,000,000 in
Federal Fiscal Year (FYY) 2022 funds,
and an estimated $2,000,000 for each
subsequent 12-month budget period
over five years, subject to availability of
funds.
Authority: This program is authorized
under Public Health Service Act,
Section 307 (42 U.S.C. 242l).
Period of Performance: September 30,
2022 through September 29, 2027.
Dated: January 11, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2022–00704 Filed 1–13–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–CE–22–011: Understanding
Polydrug Use Risk and Protective
Factors, Patterns, and Trajectories to
Prevent Drug Overdose.
Date: May 3–4, 2022.
Time: 8:30 a.m.–5:30 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Mikel Walters, Ph.D., Scientific Review
E:\FR\FM\14JAN1.SGM
14JAN1
]]>Agencies
[Federal Register Volume 87, Number 10 (Friday, January 14, 2022)]
[Notices]
[Pages 2439-2440]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00718]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of
[[Page 2440]]
which would constitute a clearly unwarranted invasion of personal
privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel; (SEP)--CE22-009, Rigorous Evaluation of
Community-Level Substance Use and Overdose Prevention Frameworks that
Incorporate ACEs-Related Prevention Strategies.
Date: April 26-27, 2022.
Time: 8:30 a.m., EDT.
Place: Web Conference..
Agenda: To review and evaluate grant applications.
For Further Information Contact: Aisha L. Wilkes, M.P.H.,
Scientific Review Official, National Center for Injury Prevention and
Control, CDC, 4770 Buford Highway NE, Mailstop S106-9, Atlanta, Georgia
30341, Telephone (404)639-6473, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-00718 Filed 1-13-22; 8:45 am]
BILLING CODE 4163-18-P
